Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Verisign, Inc. — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Verisign, Inc. trades at $302.35 (market cap $27.28B). The key difference: Verisign, Inc. is far larger — about 3.2× Hinge Health Inc. Class A Common Stock's market cap, and Verisign, Inc. pays a 1.07% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Verisign, Inc. for 124 Days on average.
| HNGE | VRSN | |
|---|---|---|
Market Cap | $8.48B | $27.28B |
Volume | 879,799 | 695,583 |
Sector | Health | Technology |
52-Week High | $105.14 | $310.00 |
52-Week Low | $31.17 | $211.49 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $8.10B | $28.59B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
VeriSign (VRSN) trades at $301.41, down 0.43% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $348. The stock shows strong profitability with a net income margin near 50% and consistent revenue growth, though recent quarterly EPS results have been mixed. Key developments include an upcoming Q3 2026 earnings report and ongoing institutional accumulation, balanced by an antitrust lawsuit and insider selling activity.
The outlook for VRSN remains positive given its dominant market position and high margins, with potential upside to analyst targets. Risks include legal challenges, competitive pressures, and valuation multiples above industry averages. Earnings performance and resolution of regulatory issues will be critical near-term catalysts for the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
